1. Home
  2. IONQ vs BBIO Comparison

IONQ vs BBIO Comparison

Compare IONQ & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IonQ Inc.

IONQ

IonQ Inc.

HOLD

Current Price

$43.06

Market Cap

18.9B

Sector

Industrials

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$84.76

Market Cap

15.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IONQ
BBIO
Founded
2015
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9B
15.9B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
IONQ
BBIO
Price
$43.06
$84.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
25
Target Price
$66.69
$86.33
AVG Volume (30 Days)
18.5M
2.0M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,235,000,000.00
$502,076,000.00
Revenue This Year
$84.91
$89.45
Revenue Next Year
$53.45
$73.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
126.26
52 Week Low
$25.89
$46.81
52 Week High
$84.64
$93.42

Technical Indicators

Market Signals
Indicator
IONQ
BBIO
Relative Strength Index (RSI) 53.86 63.11
Support Level $38.88 $78.90
Resistance Level $54.53 $93.42
Average True Range (ATR) 2.60 2.70
MACD 1.60 -0.18
Stochastic Oscillator 87.08 61.86

Price Performance

Historical Comparison
IONQ
BBIO

About IONQ IonQ Inc.

IonQ Inc sells access to several quantum computers of various qubit capacities and is in the process of researching and developing technologies for quantum computers with increasing computational capabilities. The company currently makes access to its quantum computers available via cloud platforms and also to select customers via its own cloud service. This cloud-based approach enables the broad availability of quantum-computing-as-a-service (QCaaS). The company derives its revenue from its quantum-computing-as-a-service arrangements, consulting services related to co-developing algorithms on company's quantum computing systems and contracts associated with the design, development, and construction of specialized quantum computing systems together with related services.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: